• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Consumers

  • Print
  • Share
  • E-mail

Viral Hepatitis Therapies

Click on drug brand name for additional information.

Approved Treatments for Hepatitis B
Brand NameGeneric NamesManufacturer NameIndication
BaracludeentecavirBristol-Myers Squibbchronic hepatitis B virus infection with evidence of active viral replication
Epivir-HBVlamivudineGlaxoSmithKlinechronic hepatitis B associated with
hepatitis B viral replication and active liver inflammation
Hepseraadefovir dipivoxilGilead Scienceschronic hepatitis B in patients ≥12 years of age
Intron Ainterferon alpha-2bScheringchronic hepatitis B in patients 1 year of age or older with compensated liver disease
Pegasyspegylated interferonRochetreatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation
TyzekatelbivudineNovartischronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
VireadtenofovirGilead Scienceschronic hepatitis B in adults.

 

Approved Treatments for Hepatitis C
Brand NameGeneric NamesManufacturer Name

Indication

 

SovaldisofosbuvirGilead Sciences
SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
OlysiosimeprevirJanssen
OLYSIO is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
IncivektelaprevirVertexin combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers
VictrelisboceprevirMerck & Co.treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (≥18 years of age) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.
Pegasyspegylated interferonRochetreatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha
CoPegusribavirinRocheuse in combination with Pegasys or with Roferon for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha
Pegintronpegylated interferon alpha-2bSchering

in combination with rebetol, is indicated for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease

 

use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age and intolerant to ribavirin

Intron Ainterferon alpha-2bScheringtreatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive
RebetolribavirinScheringuse in combination with Pegintron for treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age
Roferoninterferon alpha-2aRochetreatment of chronic hepatitis C in patients 18 years of age or older
Infergeninterferon aphacon-1Three Rivers Pharmatreatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or HCV RNA